Osteoblastoma
When diagnosing osteoblastoma, the preliminary radiologic workup should consist of radiography of the site of the patient's pain. However, computed tomography (CT) is often necessary to support clinical and plain radiographic findings suggestive of osteoblastoma and to better define the margins of the lesion for potential surgery. CT scans are best used for the further characterization of the lesion with regard to the presence of a nidus and matrix mineralization. MRI aids in detection of nonspecific reactive marrow and soft tissue edema, and MRI best defines soft tissue extension, although this finding is not typical of osteoblastoma. Bone scintigraphy (bone scan) demonstrates abnormal radiotracer accumulation at the affected site, substantiating clinical suspicion, but this finding is not specific for osteoblastoma. In many patients, biopsy is necessary for confirmation.
TeraView
Due in part to its ability to recognize spectral fingerprints, terahertz pulsed imaging can be applied to provide contrast between different types of soft tissue. Also, it is a sensitive means of detecting the degree of water content and markers of cancer and other diseases. Attempts have been made to apply Terahertz to image cancers like breast, cancer as well as other diseases in medicine, oral health care, and related areas. The company announced it has been cleared by the Medicines and Healthcare products Regulatory Agency (MHRA) to trial "in-vivo" terahertz spectroscopy for bio-medical research. The trials will be held in Guy's Hospital in London and aim to determine if the technology can be applied real-time for accurate removal of cancer tissue.